Search

Your search keyword '"Vania Ramponi"' showing total 5 results
Start Over Author "Vania Ramponi" Publication Year Range Last 10 years
5 results on '"Vania Ramponi"'

1. Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature

Author

Alessandro Rizzo, Maria Concetta Nigro, Vania Ramponi, Carmine Gallo, Anna Myriam Perrone, Pierandrea De Iaco, Giovanni Frezza, Damiano Balestrini, Maika Di Benedetto, Jarno Morbiducci, Maria Abbondanza Pantaleo, and Margherita Nannini

Subjects
uterine leiomyosarcoma, uterine sarcoma, skull metastasis, uterine cancer, intracranial recurrence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Uterine leiomyosarcoma (uLMS) is a rare and aggressive malignancy with poor clinical outcomes. Even when localized, uLMS is associated with high rates of local and distant recurrences that are usually fatal. Common sites of recurrence are lung, liver, pelvic lymph nodes, and vertebral and long bones, though atypical patterns of recurrence have been described. Among them, intracranial recurrence appears as a rare finding, almost exceptional in skull and dura. We describe the case of a solitary skull metastasis from uLMS in a 39-year-old woman, which represents the third reported case of skull recurrence in literature. After multidisciplinary discussion, the patient underwent surgery and received adjuvant radiotherapy. After 4 months, she is currently alive, without evidence of extracranial disease. This case highlights the importance of suspecting and recognizing atypical and extremely rare metastasis to this region. We encourage the need for large case series in order to provide further information about cranial recurrences of uLMS taking into account the paucity of data currently available in literature and the frequently unpredictable behavior of this rare and highly lethal disease.

Published
2020
Full Text
View/download PDF

2. Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients

Author

Sofia Asioli, Filippo Friso, Vittoria Rosetti, Giorgio Palandri, Vania Ramponi, Matteo Martinoni, Maria Pia Foschini, Paola Rucci, Arianna Rustici, Filippo Badaloni, Carmelo Lucio Sturiale, Carlo Bortolotti, Enrico Franceschi, Alessandro Carretta, Viscardo Paolo Fabbri, Matteo Zoli, Diego Mazzatenta, Alfredo Conti, Alba A. Brandes, Friso F., Rucci P., Rosetti V., Carretta A., Bortolotti C., Ramponi V., Martinoni M., Palandri G., Zoli M., Badaloni F., Franceschi E., Asioli S., Fabbri V.P., Rustici A., Foschini M.P., Brandes A.A., Mazzatenta D., Sturiale C., and Conti A.

Subjects
medicine.medical_specialty, Open biopsy, Survival, Brain tumor, Fluid-attenuated inversion recovery, Neurosurgical Procedures, Biopsy, medicine, Humans, Extent of resection, Progression-free survival, Karnofsky Performance Status, Retrospective Studies, Glioblastoma multiforme (GBM), medicine.diagnostic_test, Brain Neoplasms, business.industry, Proportional hazards model, Magnetic resonance imaging, medicine.disease, Multifocal GBM, Surgery, Neurology (clinical), Radiology, Multifocal Glioblastomas, Glioblastoma, business, Multicentric GBM
Abstract

BACKGROUND: Glioblastoma with multiple localizations (mGBMs) can be defined as multifocal, where enhancing lesions present a connection visible on magnetic resonance imaging fluid-attenuated inversion recovery imaging, or multicentric, in the absence of a clear dissemination pathway. OBJECTIVE: To evaluate the role of the extent of resection (EOR) in the treatment of mGBMs and its correlation with overall survival (OS) and progression free survival (PFS). METHODS: One hundred patients with mGBMs were treated at our Institution between 2009 and 2019. Clinical, radiological, and follow-up data were collected. EOR of the contrast-enhancing part of lesions was classified as gross total resection (GTR, absence of tumor remnant), subtotal resection (STR, residual tumor30%of the initial mass), and needle or open biopsy (residual tumor>75%of the initial mass). RESULTS: Approximately 15% of patients underwent GTR, 14% STR, 32% PR, and 39% biopsy. Median OS was 17 mo for GTR, 11 mo for STR, 7 mo for PR, and 5 mo for biopsy. Greater EOR was associated with a significantly longer OS than biopsy. GTR and STR were associated with a longer PFS in Kaplan-Meier survival analyses. After adjusting for age, Karnofsky performance status (KPS), number of lesions, and adjunctive therapy in multivariable Cox regression analyses, GTR, STR, and PR were still associated with OS, but only GTR remained associated with PFS. CONCLUSION: Our study suggests that EOR may positively influence survival of patients with mGBM. Surgical resection can be a reasonable option when performance and access to adjuvant treatment can be preserved.

Published
2021

3. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Enrico Franceschi, Alicia Tosoni, Santino Minichillo, Roberta Depenni, Alexandro Paccapelo, Stefania Bartolini, Maria Michiara, Giacomo Pavesi, Benedetta Urbini, Girolamo Crisi, Michele A. Cavallo, Luigino Tosatto, Claudio Dazzi, Claudia Biasini, Giuseppe Pasini, Damiano Balestrini, Francesca Zanelli, Vania Ramponi, Antonio Fioravanti, Ermanno Giombelli, Dario De Biase, Agostino Baruzzi, Alba A. Brandes, A. Baruzzi, F. Albani, F. Calbucci, R. D'Alessandro, R. Michelucci, A. Brandes, V. Eusebi, S. Ceruti, E. Fainardi, R. Tamarozzi, E. Emiliani, M. Cavallo, E. Franceschi, A. Tosoni, F. Fiorica, A. Valentini, R. Depenni, C. Mucciarini, G. Crisi, E. Sasso, C. Biasini, L. Cavanna, D. Guidetti, N. Marcello, A. Pisanello, A.M. Cremonini, G. Guiducci, S. de Pasqua, S. Testoni, R. Agati, G. Ambrosetto, A. Bacci, E. Baldin, A. Baldrati, E. Barbieri, S. Bartolini, E. Bellavista, F. Bisulli, E. Bonora, F. Bunkheila, V. Carelli, M. Crisci, P. Dall'Occa, D. de Biase, S. Ferro, C. Franceschi, G. Frezza, V. Grasso, M. Leonardi, G. Marucci, L. Morandi, B. Mostacci, G. Palandri, E. Pasini, M. Pastore Trossello, A. Pession, R. Poggi, P. Riguzzi, R. Rinaldi, S. Rizzi, G. Romeo, F. Spagnolli, P. Tinuper, C. Trocino, M. Dall'Agata, M. Frattarelli, G. Gentili, A. Giovannini, P. Iorio, U. Pasquini, G. Galletti, C. Guidi, W. Neri, A. Patuelli, S. Strumia, M. Faedi, M. Casmiro, A. Gamboni, F. Rasi, G. Cruciani, P. Cenni, C. Dazzi, A.R. Guidi, F. Zumaglini, A. Amadori, G. Pasini, M. Pasquinelli, E. Pasquini, A. Polselli, A. Ravasio, B. Viti, M. Sintini, A. Ariatti, F. Bertolini, G. Bigliardi, P. Carpeggiani, F. Cavalleri, S. Meletti, P. Nichelli, E. Pettorelli, G. Pinna, E. Zunarelli, F. Artioli, I. Bernardini, M. Costa, G. Greco, R. Guerzoni, C. Stucchi, C. Iaccarino, M. Ragazzi, R. Rizzi, G. Zuccoli, P. Api, F. Cartei, M. Colella, E. Fallica, M. Farneti, A. Frassoldati, E. Granieri, F. Latini, C. Monetti, A. Saletti, R. Schivalocchi, S. Sarubbo, S. Seraceni, M.R. Tola, B. Urbini, G. Zini, C. Giorgi, E. Montanari, D. Cerasti, P. Crafa, I. Dascola, I. Florindo, E. Giombelli, S. Mazza, V. Ramponi, F. Servadei, E.M. Silini, P. Torelli, P. Immovilli, N. Morelli, C. Vanzo, C. Nobile, Franceschi, Enrico, Tosoni, Alicia, Minichillo, Santino, Depenni, Roberta, Paccapelo, Alexandro, Bartolini, Stefania, Michiara, Maria, Pavesi, Giacomo, Urbini, Benedetta, Crisi, Girolamo, Cavallo, Michele A., Tosatto, Luigino, Dazzi, Claudio, Biasini, Claudia, Pasini, Giuseppe, Balestrini, Damiano, Zanelli, Francesca, Ramponi, Vania, Fioravanti, Antonio, Giombelli, Ermanno, De Biase, Dario, Baruzzi, Agostino, Brandes, Alba A., PERNO Study Group, Francesca, Bisulli, Valerio, Carelli, and Paolo, Tinuper

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Multivariate analysis, Methyltransferase, Kaplan-Meier Estimate, DNA methyltransferase, Methylation, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Biomarkers, Tumor, Medicine, Humans, DNA Modification Methylases, Aged, Proportional Hazards Models, Sex Characteristics, PERNO, business.industry, Brain Neoplasms, Standard treatment, Tumor Suppressor Proteins, Hazard ratio, Gender, DNA Methylation, Middle Aged, medicine.disease, Glioblastoma, MGMT, Prognosis, Confidence interval, DNA Repair Enzymes, 030220 oncology & carcinogenesis, Surgery, Neurology (clinical), Female, business, 030217 neurology & neurosurgery
Abstract

Background: Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. Methods: We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. Results: A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242-0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002-1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948-0.982; P < 0.001) were significantly correlated with survival. Conclusions: Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.

Published
2018

4. PATH-36. REPEATING TESTING IN IDH WILD TYPE LGG CASES. THE IMPORTANCE OF NEXT GENERATION SEQUENCING

Author

Santino Minichillo, Alicia Tosoni, A. Fioravanti, Enrico Franceschi, Alessio Cubeddu, Annalisa Pession, Enrico Maria Silini, Alba A. Brandes, Giovanni Tallini, Sabrina Rossi, Dario de Biase, Vania Ramponi, Marina Paola Gardiman, Antonella Mura, Elena Zunarelli, Alexandro Paccapelo, Daniela Danieli, Daniela Bartolini, Lorenzo Volpin, Michela Visani, Stefano Pizzolitto, C Bortolotti, and Stefania Bartolini

Subjects
Genetics, Cancer Research, Oncology, Path (graph theory), Wild type, Idh2 gene, Neurology (clinical), Biology, DNA sequencing
Published
2017
Full Text
View/download PDF

5. Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?

Author

Marina Paola Gardiman, Sabrina Rossi, Stefania Bartolini, Lorenzo Volpin, Enrico Franceschi, Maria Pia Foschini, Daniela Bartolini, Stefano Pizzolitto, Giovanni Tallini, Dario de Biase, Antonella Mura, Enrico Di Oto, A. Fioravanti, Alicia Tosoni, Alba A. Brandes, Vania Ramponi, Daniela Danieli, Santino Minichillo, Alexandro Paccapelo, and Annalisa Pession

Subjects
Cancer Research, medicine.medical_specialty, IDH1, medicine.diagnostic_test, business.industry, Mean age, Partial resection, Complete resection, Gastroenterology, Idh mutation, Surgery, 03 medical and health sciences, 0302 clinical medicine, Oncology, Median follow-up, 030220 oncology & carcinogenesis, Internal medicine, Biopsy, medicine, Low-Grade Glioma, business, 030217 neurology & neurosurgery
Abstract

2017 Background: Molecular characterization of low grade gliomas (LGG) is essential for diagnosis and treatment of these diseases. LGG patients (pts) with IDH mutation and 1p19q codeletion (codel) are characterized by a median OS (mOS) longer than 10 years. Thus, the role of treatments and side effects should be carefully evaluated. Methods: We evaluated LGG pts from our data warehouse (n=679 pts) who received surgery and had sufficient tissue to assess biomarkers characterization. Pts with gliomatosis were excluded. IDH1/2 assessment was performed on formalin-fixed paraffin-embedded samples by qPCR. In wild type cases we performed NGS. 1p/19 codel analysis was performed by FISH. Results: 93 consecutive LGG with IDH mutation and codel were included. The median follow up (FU) was 96.1 months. Mean age was 40 yrs (range: 25-66); 8 pts (8.6%) underwent biopsy, 61 pts (65.6%) partial resection, 24 pts (25.8%) complete resection. 84 pts (90.3%) were considered high risk using RTOG criteria (>40 years and/or incomplete resection). Fifty pts (53.7%) received only FU, 17 pts (18.3%) received chemotherapy (CT), 18 pts (19.4%) received radiotherapy (RT), 8 pts (8.6%) received RT + CT. Median PFS (mPFS) was 59.6 months (95%CI: 41.8-77.4) and was significantly longer in pts who received postsurgical treatments (79.5 months, 95%CI: 66.4-92.7) than pts who received FU (46.3 months, 95%CI: 36.0-56.5; P=0.001). mPFS was 50.8 months (95%CI: 17.4-84.3), 103.6 months (95%CI: 11.7-195.6) and 120.2 months (95%CI: 40.5-199.8) in pts treated with CT alone, RT alone and RT + CT, respectively. Multivariate analysis showed that receiving a post-surgical treatment (P

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results